STOCK TITAN

Benitec Biopharma Inc - BNTC STOCK NEWS

Welcome to our dedicated news page for Benitec Biopharma (Ticker: BNTC), a resource for investors and traders seeking the latest updates and insights on Benitec Biopharma.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Benitec Biopharma's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Benitec Biopharma's position in the market.

Rhea-AI Summary
Benitec Biopharma Inc. (NASDAQ: BNTC) will effect a 1-for-17 reverse stock split of its common stock to maintain its listing on Nasdaq. The split will become effective on July 26, 2023, and the stock will begin trading on a split-adjusted basis. The reverse split will combine 17 current shares into one share. No fractional shares will be issued.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.79%
Tags
none
-
Rhea-AI Summary
Benitec Biopharma has received FDA clearance for its Investigational New Drug (IND) application for BB-301, a gene therapy for the treatment of Oculopharyngeal Muscular Dystrophy-related Dysphagia. The first subject is expected to be dosed in the second half of 2023, following the rollover of subjects from the ongoing Natural History (NH) study. OPMD is a chronic, life-threatening genetic disorder affecting approximately 15,000 patients in the United States, Canada, Western Europe, and Israel. Currently, there are no approved therapeutic agents for the treatment of OPMD.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
80.9%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.94%
Tags
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.93%
Tags
conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.93%
Tags
conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
9.44%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.37%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-15.38%
Tags
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-28.35%
Tags
Benitec Biopharma Inc

Nasdaq:BNTC

BNTC Rankings

BNTC Stock Data

12.39M
2.02M
6.81%
55.14%
0.42%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
Australia
Melbourne

About BNTC

benitec biopharma is using patented ‘gene-silencing’ technology to develop drugs for chronic and life-threatening human diseases. our transformational technology, ddrnai, targets and ‘turns off’ specific genes related to disease, providing lasting treatment and potentially cure with a single dose. compared to traditional approaches to rna intereference, ddrnai is easier to deliver, safer to us, more targeted and more efficient. benitec has a pipeline of in-house and partnered drug development programs based on ddrnai, including hepatitis c and b and cancer-associated pain. ddrnai has the potential to silence genes related to thousands of human diseases and is protected by over 40 global patents. the technology is available from benitec under a variety of licence options.